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Superficial Morphea of the Lips and Gingiva
Morphea is a cutaneous disorder characterized 
by excessive collagen deposition. While in almost all 
cases the sclerosing process exclusively affects the 
skin, there are anecdotal cases in which associated 
mucosal involvement has been described. In 1999 
McNiff et al. (1) described the first cases of superficial 
morphea, presenting as pigmented mucosal lesions 
with minimal cutaneous induration. Previously, it had 
been speculated that morphea might result from au-
toimmunity, infection, drugs, etc (2). Recently, it has 
been suggested that morphea might be preceded by 
trauma and radiation (3,4). Most of the patients with 
oral morphea described in the literature suffered 
from scar-like or indurated whitish lesions of the oral 
mucosa, unerupted teeth, root development defects, 
root atrophy, localized gingival recession, and alveo-
lar bone resorption (5). Furthermore, other orodental 
abnormalities such as widening of the periodontal 
space, temporomandibular disorders, and limited 
mouth opening have been reported in patients with 
scleroderma. To our knowledge, there are around 25 
cases of morphea associated with oral and dental 
manifestations reported in the literature (5).It is still a 
matter of debate which treatment option is the most 
efficient (6).
A 38-year-old female patient was referred to our 
Department due to the hypopigmented lesion ex-
tending from the lip to the base of the nose (Figure 1). 
Clinical examination revealed that the hypopigment-
ed area also extended to the corresponding mucosal 
side of the lip and on the gingiva adjacent to tooth 
#22. The patient had a history of trauma (swinging 
blow) in that area 1.5 years ago. Three months before 
admittance to our Department she had tooth #22 
extracted because of excessive mobility. The patient 
was concerned as the lesion slowly increased in size. 
The patient suffered from occasional minor gas-
tric discomfort but was otherwise healthy. She had no 
history of radiation, autoimmune diseases, Raynaud’s 
phenomenon, etc. Serum testings did not reveal thy-
roid abnormalities or pernicious anemia. C-reactive 
protein, glucose levels, liver enzymes, creatinine, lac-
tate dehydrogenase, serum potassium, sodium, cal-
cium, and phosphates were within normal ranges. As 
she mentioned a tick bite last year, she was sent for a 
Borrelia antibodies test which revealed no abnormali-
ties. Human immunodeficiency virus (HIV), hepatitis 
B, C, and syphilis serology were negative.
Histopathology of the mucosal lesion showed 
thickened, parakeratotic epithelium without sig-
nificantly expressed papillomatosis together with 
intensely dense and hyalinized collagen in the un-
derlying stroma as well as significant reduction of 
elastic fibers and their occasional spread into sur-
rounding adipose tissue. Inflammatory infiltrate was 
quite sparse and with focally arranged cells, mostly 
consisting of lymphocytes. The finding was highly 
suggestive of localized scleroderma i.e. morphea. All 
antinuclear antibodies including anti-topoisomerase 
I antibodies were negative. Protein electrophoresis, 
immunoglobulins, and C3 as well as C4 were within 
normal ranges. A clinical immunologist concluded 
that the patient did not meet the criteria for the diag-
nosis of systemic sclerosis.
The patient was treated with zinc supplement (90 
mg daily) together with 1% pimecrolimus ointment 
(Elidel®, Valeant Pharmaceuticals, Montreal, Canada) 
over two months, but there was no improvement. Fol-
lowing that, topical asiaticoside ointment (Shanghai 
Modern Pharmaceuticals Co, Shangai, China) and oral 
Salvia miltiorhiza (Tianjin Tasly Pharmaceutical Co, 
Tianjin, China) in total duration of nine months were 
used, again with no improvement. Subsequently, 
weekly intralesional steroid injections (methylpred-
nisolone acetate, Depo Medrol®, Pfizer Inc. NY, USA, 
16 mg divided into four sites on the mucosal side of 
the lip), together with topical 0.05% bethametasone 
acetate ointment (Beloderm®, Belupo, Koprivnica, 
Croatia) three times a day were introduced. The lesion 
fully resolved after eight weekly intralesional applica-
tions (Figure 2).
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DISCUSSION
Upon admission the list of differential diagnosis 
affecting the skin and mucosa included scleroderma, 
lichen sclerosus, vitiligo, Lyme disease, graft-versus-
host disease, morphea-type basal cell carcinoma, 
atrophoderma of Pasini and Pierini, verruciform xan-
thoma, eosinophilia-myalgia syndrome, mycosis fun-
goides, gadolinium induced changes, oral submu-
cous fibrosis, leukoplakia, plaque type lichen, chronic 
candidiasis, sideropenic anemia, fibrous scar, white 
sponge nevus, etc (7). However, histopathology re-
vealed the straightforward diagnosis of morphea in 
our patient.
Detailed medical history revealed a tick bite one 
year ago. Since manifestations of Lyme disease might 
look similar to these lesions, the patient was referred 
to the infectologist. No increase in Borrelia burgdorferi 
titers was noticed and she was negative for HIV, hepa-
titis B, C and syphilis (8). 
Furthermore, our patient was occasionally taking 
proton pump inhibitors. Therefore, drugs were ex-
cluded as a possible cause of morphea.
As seen in other cases, morphea in our patient 
was preceded by trauma in that area (after a swinging 
blow). No widening of the periodontal ligament and 
no other oral signs of scleroderma were seen in our 
patient, such as limited mouth opening, xerostomia, 
temporomandibular joint disease, skeletal asymme-
try, unerupted teeth, root development defects, root 
atrophy, localized gingival recession, and alveolar 
bone resorption (5,9).
There is a wide range of treatment options for 
cutaneous morphea, such as topical and systemic 
therapies as well as phototherapy, but randomized 
controlled trial evidence is still lacking (6). In our case 
phototherapy was excluded due to the lesion loca-
tion i.e. the face. On the other hand, treatment op-
tions for oral mucosal morphea are very scarce. 
Brocard et al. (10) published a retrospective study 
on 17 patients with histologically confirmed local-
ized scleroderma active for more than one year and 
whose treatment with a high potency dermocortico-
steroid was a failure. The patients were then treated 
with 60 to 90 mg of zinc gluconate daily for three 
months. An efficacy of 53% was obtained (5 partial 
remissions and 4 complete remissions) with a mean 
dose of 83.3 mg/day. Two patients (11.8%) had gastric 
discomfort that did not require treatment discontin-
uation. Therefore, the dose of 90 mg zinc gluconate 
daily was introduced in our patient, but no improve-
ment after two months was observed. Moreover, the 
patient reported worsening of her gastric discomfort. 
During the same time she also applied 1% pimecro-
limus oitnment on the affected area, again with no 
improvement.
We then started topical therapy suggested by Liu 
et al. (11) based on the application of topical asiati-
coside ointment (Shanghai Modern Pharmaceuticals 
Co, Shangai, China) and oral Salvia miltiorhiza (Tianjin 
Tasly Pharmaceutical Co, Tianjin, China). The authors 
reported this treatment to be beneficial in two pa-
tients after nine months. However, this treatment was 
not efficient in our patient.
Finally we started treatment with intralesional ste-
roid injections. A case report of intralesional steroid 
injection and topical calcipotriene treatment was 
described by Hanson et al. (17) in a 17 year woman 
suffering from morphea on her left flank, however 
without success. This finding is in contrast to ours as 
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Figure 1. Finding on the upper lip at the initial pre-
sentation of the patient.
Figure 2. Intraoral fnding at the initial presentation 
of the patient.
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lesions seen in our patient subsided after eight week-
ly intralesional steroid injections. 
As stated by other authors, evidence based thera-
py for oral mucosal morphea is almost entirely lacking 
and management of oral lesions is challenging. When 
there is only local involvement, i.e. morphea and there 
are no signs of systemic involvement (scleroderma), it 
seems that topical therapies are worth trying. 
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